Literature DB >> 21194354

Oxidative stress in schizophrenia: pathogenetic and therapeutic implications.

Jeffrey K Yao1, Ravinder Reddy.   

Abstract

Over a century, a wide-ranging variety of pathophysiological models and causal hypotheses have been conceptualized for schizophrenia. One among these is the role for free radical-mediated pathology in schizophrenia, indicating impaired antioxidant defense system (AODS) and presence of oxidative stress in patients with schizophrenia. For the past two decades, the whole investigative domain of AODS and oxidative stress has broadened to include the wider AODS components, direct central nervous system assays of AODS, chemical imaging studies, proteomics, genetics of AODS, and, of importance to sufferers of schizophrenia, antioxidant therapeutics. These are some of the perspectives that are reviewed by several articles in this Forum. Overall, there has been growing recognition of the importance of oxidative stress in the pathophysiology of schizophrenia and in treatment-related side effects. The totality of the evidence from biochemistry, metabolomics, proteomics, genetics, and in vivo brain imaging points to the presence of multifarious abnormalities in the AODS and redox signaling in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21194354      PMCID: PMC3159103          DOI: 10.1089/ars.2010.3646

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  33 in total

Review 1.  Antioxidant therapeutics for schizophrenia.

Authors:  Ravinder Reddy; Rajiv Reddy
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

Review 2.  Supramolecular structure of the mitochondrial oxidative phosphorylation system.

Authors:  Egbert J Boekema; Hans-Peter Braun
Journal:  J Biol Chem       Date:  2006-11-13       Impact factor: 5.157

3.  2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia.

Authors:  Sudhakaran Prabakaran; Martina Wengenroth; Helen E Lockstone; Kathryn Lilley; F Markus Leweke; Sabine Bahn
Journal:  J Proteome Res       Date:  2007-01       Impact factor: 4.466

Review 4.  Redox dysregulation, neurodevelopment, and schizophrenia.

Authors:  Kim Q Do; Jan H Cabungcal; Anita Frank; Pascal Steullet; Michel Cuenod
Journal:  Curr Opin Neurobiol       Date:  2009-05-27       Impact factor: 6.627

Review 5.  Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E.

Authors:  J L Cadet; J B Lohr
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

6.  Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia.

Authors:  René Gysin; Rudolf Kraftsik; Olivier Boulat; Pierre Bovet; Philippe Conus; Emily Comte-Krieger; Andrea Polari; Pascal Steullet; Martin Preisig; Tanja Teichmann; Michel Cuénod; Kim Q Do
Journal:  Antioxid Redox Signal       Date:  2010-10-30       Impact factor: 8.401

Review 7.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

8.  Direct analysis of protein complexes using mass spectrometry.

Authors:  A J Link; J Eng; D M Schieltz; E Carmack; G J Mize; D R Morris; B M Garvik; J R Yates
Journal:  Nat Biotechnol       Date:  1999-07       Impact factor: 54.908

9.  Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.

Authors:  C A Tamminga; G K Thaker; R Buchanan; B Kirkpatrick; L D Alphs; T N Chase; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1992-07

Review 10.  Mitochondria, synaptic plasticity, and schizophrenia.

Authors:  Dorit Ben-Shachar; Daphna Laifenfeld
Journal:  Int Rev Neurobiol       Date:  2004       Impact factor: 3.230

View more
  21 in total

Review 1.  Oxidative Stress and the Central Nervous System.

Authors:  Samina Salim
Journal:  J Pharmacol Exp Ther       Date:  2016-10-17       Impact factor: 4.030

2.  Metabolomic profiling on rat brain of prenatal malnutrition: implicated for oxidative stress and schizophrenia.

Authors:  Fei Xu; Xin Li; Weibo Niu; Gaini Ma; Qianqian Sun; Yan Bi; Zhenming Guo; Decheng Ren; Jiaxin Hu; Fan Yuan; Ruixue Yuan; Lei Shi; Xingwang Li; Tao Yu; Fengping Yang; Lin He; Xinzhi Zhao; Guang He
Journal:  Metab Brain Dis       Date:  2019-08-13       Impact factor: 3.584

3.  Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

4.  Differential effects of antipsychotics on the development of rat oligodendrocyte precursor cells exposed to cuprizone.

Authors:  Haiyun Xu; Hong-Ju Yang; Xin-Min Li
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-06-01       Impact factor: 5.270

Review 5.  Perineuronal nets and schizophrenia: the importance of neuronal coatings.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2014-04-04       Impact factor: 8.989

6.  Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium.

Authors:  Kristin S Cadenhead; Amedeo Minichino; Skylar Kelsven; Jean Addington; Carrie Bearden; Tyrone D Cannon; Barbara A Cornblatt; Dan Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming Tsuang; Elaine F Walker; Scott W Woods; Jeff Yao
Journal:  Schizophr Res       Date:  2018-09-22       Impact factor: 4.939

Review 7.  Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases.

Authors:  Grace Y Sun; Agnes Simonyi; Kevin L Fritsche; Dennis Y Chuang; Mark Hannink; Zezong Gu; C Michael Greenlief; Jeffrey K Yao; James C Lee; David Q Beversdorf
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2017-03-10       Impact factor: 3.015

8.  Altered glycogen metabolism in cultured astrocytes from mice with chronic glutathione deficit; relevance for neuroenergetics in schizophrenia.

Authors:  Suzie Lavoie; Igor Allaman; Jean-Marie Petit; Kim Q Do; Pierre J Magistretti
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

Review 9.  Metabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolites.

Authors:  Jia Liu; Lawrence Litt; Mark R Segal; Mark J S Kelly; Jeffrey G Pelton; Myungwon Kim
Journal:  Int J Mol Sci       Date:  2011-09-28       Impact factor: 5.923

10.  Nucks1 gene polymorphism rs823114 is associated with the positive symptoms and neurocognitive function of patients with schizophrenia in parts of southern China.

Authors:  Xia Wen; Xusan Xu; Xudong Luo; Jinwen Yin; Chunmei Liang; Jinyuan Zhu; Xueyan Nong; Xiudeng Zhu; Fan Ning; Shanshan Gu; Susu Xiong; Jiawu Fu; Dongjian Zhu; Zhun Dai; Dong Lv; Zhixiong Lin; Juda Lin; You Li; Guoda Ma; Yajun Wang
Journal:  Psychiatr Genet       Date:  2021-08-01       Impact factor: 2.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.